About US
Contact us
-
Don't worry, Pfizer and Allergan. Treasury just did you a favorPfizer ($PFE) and Allergan ($AGN) may feel pained by the collapse of their $160 billion merger. But when the U.S. Treasury cracked down on the deal with new tax-inversion rules, it may have done the t2016/4/7
-
AstraZeneca and Takeda DPP-4 inhibitors get another warning added to their labelsThere is more bad news for DPP-4 inhibitor diabetes drugs saxagliptin and alogliptin from AstraZeneca ($AZN) andTakeda. TheFDAhas tightened its regulatory grip on the Type 2 diabetes meds, insisting t2016/4/7
-
Pfizer escapes hundreds of lawsuits alleging birth defects tied to ZoloftPfizer ($PFE) chalked up a big win in its courtroom saga over alleged birth defects tied to its antidepressantZoloft. A federal judge agreed to dismiss the vast majority of claims against the company2016/4/6
-
Allergan ushers #ActuallySheCan campaign onto Tribeca festival screensAllergan ($AGN) is taking its hashtag-heavy, emoji-laden female empowerment campaign, #ActuallySheCan, to the Tribeca Film Festival. Three women directors created films featuring three women aiming at2016/4/6
-
Bayer invests in U.S. growth to get it through its big transitionsPlenty ofBayer's peers are focusing their expansion efforts outside the U.S., on emerging markets with more growth potential. But not the German pharma. Instead, it's working to boost its presence an2016/4/5
-
Roche softens tone with U.K., says it is willing to try pay-for-performance pricingSince name-calling didn't get Roche ($RHHBY) the results it wanted with U.K. drug price watchdogs, executives are trying a new tactic: conciliation. The drugmaker has indicated it is open to price neg2016/4/5
-
Will SCOTUS take up Sandoz' pivotal biosim case? New briefs call on court to weigh inBiosimilars advocates are lining up behindSandozto persuade the U.S. Supreme Court to take up its case against Amgen ($AMGN). The closely watched legal tussle, over Sandoz's biosim copy Amgen's blockb2016/4/1
-
Label surprise boosts Jazz as it preps Defitelio rolloutIt's been a long road to FDA approval for Jazz Pharmaceuticals' ($JAZZ) Defitelio. But the Irish biotech is finally ready to launch the product--and a surprise on the product's label may help make tha2016/4/1
-
Bayer and Regeneron to develop combination therapy to treat eye diseasesBayer and Regeneron Pharmaceuticals have jointly developed a combination therapy for the treatment of eye diseases. Through the collaboration, Regeneron will combine its angiopoietin2 (Ang2) antibody2016/3/31
-
Sun Pharma to sell AstraZeneca's Type 2 diabetes medicine in IndiaSun Pharmaceutical Industries has entered a partnership with AstraZeneca to sell the latter's Type 2 diabetes (T2D) medicine, dapagliflozin, in India. Both firms have signed a distribution agreement.2016/3/31